SCHEDULE 13G: Ally Bridge Group and Affiliates Disclose Significant Passive Stake in Aadi Bioscience

Ally Bridge Group and its affiliated entities, including Mr. Fan Yu, have filed a Schedule 13G disclosing their passive beneficial ownership of Aadi Bioscience, Inc. common stock, with Mr. Fan Yu holding an aggregate of 6.3%.

Summary

• Ally Bridge Group and its various affiliated entities, along with Mr. Fan Yu, have filed a Schedule 13G indicating their beneficial ownership in Aadi Bioscience, Inc.
• The filing reports beneficial ownership of Aadi Bioscience, Inc. common stock, par value $0.0001 per share, based on 46,294,912 shares outstanding as of March 4, 2025.
• Mr. Fan Yu, as the controlling stockholder of key entities within Ally Bridge Group, is reported to beneficially own an aggregate of 2,914,605 shares, representing 6.3% of Aadi Bioscience's common stock.
• Ally Bridge MedAlpha Master Fund L.P. holds 817,939 shares, representing 1.8% of the class.
• ABG Innovation-SO Limited holds 26,666 shares, representing 0.1% of the class.
• ABG V-SIV Limited holds 2,070,000 shares, representing 4.5% of the class.
• The reported beneficial ownership does not include 7,110,000 shares of Common Stock issuable upon the exercise of warrants held by ABG V-SIV Limited, which are subject to exercise limitations.
• The filing is a passive investment disclosure, with the reporting persons certifying that the securities were not acquired for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing (Schedule 13G) disclosing beneficial ownership. It does not contain performance data, strategic updates, or forward-looking statements from the issuer that would typically influence sentiment. The disclosure of a significant passive stake by an institutional investor is generally neutral to slightly positive, but the document itself is purely factual.

Positives

• The filing indicates a significant passive investment by Ally Bridge Group and its affiliates, potentially signaling confidence in Aadi Bioscience's long-term prospects from a notable institutional investor.
• The disclosure of a 6.3% stake by Mr. Fan Yu, a key figure in Ally Bridge Group, highlights a substantial commitment.

Risks

• The document explicitly states that 7,110,000 shares issuable upon exercise of warrants held by ABG V-SIV Limited are not included in the reported beneficial ownership and are subject to limitations on exercise, implying potential future dilution if these warrants become exercisable and are converted.
• The reporting persons disclaim beneficial ownership of the securities except to the extent of their pecuniary interest, which is a standard disclaimer but notes that their control over the shares is limited to their financial stake.

Future Outlook

NA

Management Comments

• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11."

Industry Context

This filing is a standard disclosure of a passive investment by an institutional investor in a publicly traded biotechnology company. It does not provide broader industry trends or competitive analysis. Ally Bridge Group is known for its investments in the life sciences sector.

Stakeholder Impact

• Shareholders: The disclosure of a significant passive stake by Ally Bridge Group and its affiliates, including Mr. Fan Yu, provides transparency regarding the ownership structure of Aadi Bioscience, Inc. This information can be relevant for other investors assessing the company's shareholder base and institutional interest.

Key Dates

Keywords

Aadi Bioscience, Ally Bridge Group, Fan Yu, Schedule 13G, beneficial ownership, common stock, institutional investment, passive stake, SEC filing, biotechnology, pharmaceutical